- Home
- IIIV vs FENC Comparison
IIIV vs FENC Comparison
Compare IIIV & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IIIV | FENC |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.0M | 384.0M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | IIIV | FENC |
|---|---|---|
| Price | $16.20 | $10.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $25.50 | $17.67 |
| AVG Volume (30 Days) | ★ 588.0K | 120.2K |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.24 | 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $2.13 | $62.55 |
| Revenue Next Year | $4.98 | $42.10 |
| P/E Ratio | ★ $66.58 | $178.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.63 | $5.65 |
| 52 Week High | $33.97 | $13.25 |
Technical Indicators
Market Signals| Indicator | IIIV | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 48.31 |
| Support Level | $15.59 | $9.87 |
| Resistance Level | $17.12 | $11.29 |
| Average True Range (ATR) | 0.63 | 0.49 |
| MACD | 0.29 | 0.03 |
| Stochastic Oscillator | 92.17 | 64.55 |
Price Performance
Historical ComparisonAbout IIIV i3 Verticals Inc.
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.